Suboptimal Suppression with Maraviroc plus a Boosted Protease Inhibitor?

Until larger studies are done, such regimens are probably best avoided.

A nucleoside reverse transcriptase inhibitor (NRTI) backbone remains standard in combination antiretroviral therapy, but there is ongoing interest in developing NRTI-sparing regimens to avoid the drugs' short- and long-term toxicities.

In a recent multinational, open-label, manufacturer-sponsored trial, 121 treatment-naive HIV-infected individuals with confirmed CCR5-tropic virus were randomized to receive ritonavir-boosted atazanavir in combination with either tenofovir/FTC or maraviroc at the unusually low dose of 150 mg once daily.

At week 48, rates of virologic suppression (HIV RNA <50 copies/mL) were 75% in the maraviroc group and 84% in the tenofovir/FTC group. The median change from baseline in CD4-cell count was similar between groups…

Reviewing Author

Abigail Zuger, MD

Disclosures

Nothing to disclose

Abigail Zuger, MD

Disclosures

Nothing to disclose

Suboptimal Suppression with Maraviroc plus a Boosted Protease Inhibitor?

Topics

Reviewing Author